We are a diversified healthcare group that is developing, investing in and delivering a range of exciting new technologies and leading edge medical devices that have the potential to make a real difference to the outcomes and quality of life of patients around the globe.Learn More
Admedus next generation vaccine technology targets HPV
2016 is looking to be an important year for Admedus as our immunotherapy programs continue to progress well. Working with Professor Ian Frazer and his team, we are developing therapeutic vaccines to target human papillomavirus (HPV) and herpes simplex virus 2 (HSV-2). These vaccines address significant diseases with a huge unmet medical need and if successful, […]
February 12th 2016Find out more
Open Letter From Mr Wayne Paterson To Shareholders
Dear Shareholders and friends of Admedus, I would like to take the opportunity to update you on current events and what you can expect from the team moving forward.
February 10th 2016Find out more
Admedus inks exclusive distro deal with Coroneo
Admedus (ASX:AHZ) has inked an exclusive distribution agreement with Coroneo to sell its extra aortic annuloplasty ring and other heart valve surgery instruments in Germany and the U.K.
January 27th 2016Find out more
Admedus HSV-2 vaccine set for key value inflection point
In an interview with leading online biotech site, BioTuesdays, Chief Operating Officer Julian Chick discusses Admedus’ anticipated interim results from a Phase 2 trial of its therapeutic vaccine for the treatment of herpes simplex virus-2 (HSV-2).
September 22nd 2015Find out more